Dr. Campagna is currently SVP, Health Sciences Lead, in the Surgery and Perioperative Care Global Innovation Group at The Medicines Company. Previously he served as VP and Global Medical Lead for Surgery and Critical Care Pathway. Prior to joining MDCO, he served as the Chief Medical Quality Officer at Cottage Health System and held faculty appointments at UC Santa Barbara in Neuroscience and Stanford University. He graduated from the combined MD/PhD program at The University of Miami with a Ph.D. in Molecular and Cellular Pharmacology, and then completed his post-doctoral fellowship at the Neural Plasticity Research Group, his Internal Medicine internship, Anesthesia and Critical Care residency and cardio-thoracic anesthesia fellowship all at the Massachusetts General Hospital in Boston. He was on faculty at Harvard Medical School, and held an academic appointment in the Department of Anesthesia and Critical Care at MGH. Dr. Campagna is a board certified critical care anesthesiologist and an oral board examiner for The American Board of Anesthesia. He also currently serves on the Board of Directors for the Neuroscience Research Institute in Santa Barbara, CA, is a Scholar in Residence at the Kennedy Institute for Bioethics at Georgetown University and holds an adjunct faculty appointment at the Massachusetts General Hospital in Boston.
What is a key relationship or turning point that helped you get to where you are today?
This is a great question. I suspect because it comes up so often in... Read more »
My phone rang late in the day on a pleasant fall afternoon. It was a close friend and business associate of mine and, because we talk often enough about a whole... Read more »
In a prior Xconomy post, I explored the unwritten and often hidden challenges of successfully navigating and completing a ‘build to buy’ acquisition. The fundamental issue that underlies those challenges... Read more »
Here’s a question for consideration: What does it mean to acquire a virtual, single asset biotech that was ‘built’ for the sole purpose of being bought? The answer is much more... Read more »